OH-PROCTER-&-GAMBLE
10.6.2020 15:02:07 CEST | Business Wire | Press release
This week, P&G Beauty convened a virtual meeting with leading global NGOs to discuss the role of the beauty industry in accelerating progress towards a more sustainable, inclusive and resilient future.
Until now, the industry has responded to consumer concerns over safety, quality, origin and sustainability with an array of claims – such as natural, organic or clean – many of which lack clear definitions and standards and are sometimes at odds with one another. The group made up of experts from various NGOs and Alex Keith, CEO, P&G Beauty, recognized that it is more vital than ever to look at these challenges as interconnected rather than individually. For the industry to become future-fit and to build business resilience, the group concluded that it must address systemic challenges through collective action, leveraging the best of science and protecting nature by purposefully bringing the two together.
P&G Beauty is addressing this through its P&G Responsible Beauty platform , a systems-thinking approach rooted in the connections and interdependence of five guiding principles: Quality & Performance; Safety; Sustainability; Transparency, and Equality & Inclusion. As part of the event, P&G Beauty shared the P&G Responsible Beauty 2030 goals (link ). One of the goals of P&G Responsible Beauty is openly sharing technologies, programs or processes that can help the beauty industry have a bigger, positive impact on the world. As a tangible first action to bring this goal to life the Company is making publicly available a comprehensive guide for the safe use of botanicals in beauty products (link ). The guide, incorporating learnings from over a decade of published research, provides formulators from small to large size beauty brands, with a robust safety approach to assess botanical ingredients and ensure their safe use in products.
The event, co-hosted by Women’s Wear Daily, was attended by media representatives from around the world, and featured P&G Beauty CEO Alex Keith and the P&G Responsible Beauty Advisory Council, an advisory group created more than a year ago to ensure P&G Beauty priorities are well informed by the most innovative, leading-edge thinking and experience. The Council is made up of representatives from Royal Botanic Gardens, Kew (a world leading authority on plant science); World Wildlife Fund (WWF); Rainforest Alliance; Skin Health Alliance; and the Roundtable on Sustainable Biomaterials.
“Making meaningful progress via responsible growth – growth rooted in systems thinking - requires partnership and collaboration,” said Alex Keith, CEO of P&G Beauty, “The P&G Responsible Beauty Advisory Council helps to ensure we are bringing external insights and experience into our decision-making, and applying systems thinking to our plans to ensure we consider the interdependencies of one choice on other critical areas.”
The panel discussion during the event covered a range of topics underscoring the extent to which human health and economic prosperity depend on a healthy, natural world, as well as how systems thinking can help the beauty industry navigate and understand today’s disruptions and provide solutions to build back better in a post-COVID world via a focus on responsible growth.
“Building business resilience in a way that supports a sustainable world, improves quality of life, respects human rights and protects the environment is possible,” said P&G Beauty’s Keith. "For beauty, this means going beyond environmental practices to address the interdependence of all aspects of product development and corporate behavior — all activities that affect the beauty consumer and the world in which we live.”
# # #
About the P&G Responsible Beauty Advisory Council Members:
Rainforest Alliance // Rainforest-alliance.org
The Rainforest Alliance works at the intersection of business, agriculture and forests to make “responsible business” the new normal, protecting forests and improving the lives of farmers and forest communities.
Roundtable on Sustainable Biomaterial // Rsb.org
The Roundtable on Sustainable Biomaterials (RSB) guides the responsible development and production of biomass, biofuels, and biomaterials through sustainability solutions, certification, and collaborative partnerships.
World Wildlife Fund // worldwildlife.org
For almost 60 years, the WWF has been protecting the future of nature. One of the world’s leading conservation organizations, WWF develops solutions to help communities and wildlife thrive.
Royal Botanic Gardens, Kew // kew.org
The global resource for plant and fungal research, the Royal Botanic Gardens, Kew uses their unparalleled expertise, botanical collections, and global partnerships to tackle the critical challenges facing humanity.
Skin Health Alliance // skinhealthalliance.org
The Skin Health Alliance collaborates with dermatologists, researchers and skin scientists to provide independent, scientifically based verification of the safety of beauty products, clinics, treatments, and services.
About P&G:
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
For more information:
https://us.pg.com/responsible-beauty/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005452/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
